Skip to Main Content

Schizophrenia Outpatient – Neurocrine-3032

About the Study

For adults with schizophrenia who do not warrant inpatient hospitalization.

The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18-65 years old

  • meet DSM-5 criteria for schizophrenia

  • are currently NOT experiencing an acute exacerbation, or relapse, of psychotic symptoms

  • has had a positive response to at least one anti-psychotic treatment (excluding Clozapine) as confirmed by medical records

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.